Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

doi:10.1200/JCO.2012.48.1390

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2013

Shepherd Frances A, Domerg Caroline, Hainaut Pierre, Jänne Pasi A, Pignon Jean-Pierre, Graziano Stephen, Douillard Jean-Yves, Brambilla Elizabeth, Le Chevalier Thierry, Seymour Lesley, Bourredjem Abderrahmane, Le Teuff Gwénaël, Pirker Robert, Filipits Martin, Rosell Rafael, Kratzke Robert, Bandarchi Bizhan, Ma Xiaoli, Capelletti Marzia, Soria Jean-Charles, Tsao Ming-Sound

Abstract excerpt

PURPOSE: We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of KRAS in non-small-cell lung cancer (NSCLC). METHODS: KRAS mutation was determined in blinded fashion. Exploratory analyses were performed to characterize relationships between mutation status and subtype and survival outcomes using a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Gene Pool

Share to Genes, ras

Share to Proto-Oncogene Proteins p21(ras)

Share to Randomized Controlled Trials as Topic

Share to ras Proteins

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 23630215
DOI: 10.1200/JCO.2012.48.1390
PMCID: PMC4881333

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.PMID 23630215Read ↗

The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.Semantic proximity Read ↗

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.Semantic proximity Read ↗

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.Semantic proximity Read ↗

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.Semantic proximity Read ↗

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.Semantic proximity Read ↗

The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.Semantic proximity Read ↗

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.Semantic proximity Read ↗

Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.Semantic proximity Read ↗

KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.Semantic proximity Read ↗

Prognostic Impact and Recurrence Pattern of KRAS G12C Mutation in Surgically Resected Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.